Lineagen Inc. Announces Identification Of New Genetic Region Associated With Seizures In Wolf-Hirschhorn Syndrome

SALT LAKE CITY--(BUSINESS WIRE)--Lineagen, Inc., an innovative genetics diagnostics company focused on complex neurodevelopmental disorders, announced today the publication of a major study revealing a significant genetic contributor to epilepsy in Wolf Hirschhorn syndrome. The study was the result of a unique collaboration between academic research institutions, a patient advocacy group known as the 4p- Support Group and Lineagen. Academic researchers hailed from the University of Utah, the Stella Maris Clinical Research Institute for Child and Adolescent Neuropsychiatry (Pisa, Italy), the University of Minnesota and the University of New Mexico.